Commentary: Biosimilars are coming, and patients could benefit

03/6/2009 | Genetic Engineering & Biotechnology News

Regulating the development of follow-on biologics as recommended in President Barack Obama's first budget could benefit patients if the law "appropriately balances the need for competition with the need to protect innovation," writes James Bianco, CEO and director of Cell Therapeutics. The law should help bring follow-on biologics to the market quickly but only after their safety and efficacy have been tested in clinical trials, Bianco writes.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC